1. Home
  2. AMCX vs CAPR Comparison

AMCX vs CAPR Comparison

Compare AMCX & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AMC Networks Inc.

AMCX

AMC Networks Inc.

SELL

Current Price

$9.11

Market Cap

492.0M

ML Signal

SELL

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

SELL

Current Price

$8.36

Market Cap

584.9M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
AMCX
CAPR
Founded
1980
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Cable & Other Pay Television Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
492.0M
584.9M
IPO Year
2011
2011

Fundamental Metrics

Financial Performance
Metric
AMCX
CAPR
Price
$9.11
$8.36
Analyst Decision
Sell
Buy
Analyst Count
8
10
Target Price
$9.50
★ $27.25
AVG Volume (30 Days)
687.2K
★ 3.6M
Earning Date
11-09-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 132.55
N/A
EPS
N/A
★ N/A
Revenue
★ $2,311,801,000.00
N/A
Revenue This Year
$5.04
N/A
Revenue Next Year
N/A
$85.77
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$6.47
$2.96
52 Week High
$12.93
$40.37

Technical Indicators

Market Signals
Indicator
AMCX
CAPR
Relative Strength Index (RSI) 46.92 50.24
Support Level $7.34 $7.78
Resistance Level $10.58 $10.42
Average True Range (ATR) 0.49 1.01
MACD 0.23 0.23
Stochastic Oscillator 69.41 45.99

Price Performance

Historical Comparison
AMCX
CAPR

About AMCX AMC Networks Inc.

AMC Global Media owns several linear TV networks, including AMC, WE tv, BBC America, IFC, and SundanceTV. AMC, its most widely distributed network,reached 55 million pay TV households in the US at the end of 2025. The firm also had nearly 10.5 million US streaming subscribers, with AMC+ as the flagship streaming platform. With both its linear networks and streaming offerings, the firm caters to specific niche audiences. Over the last 15 years, AMC has shifted its focus to original scripted programming from classic movies. It creates content through AMC Studios and also generates revenue from licensing content. Following an international divestiture at the end of 2023, domestic operations make up nearly 90% of total revenue.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: